Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab dose-interval shortening versus standard dosing in partial PASI responders with plaque psoriasis
2014-001974-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in plaque psoriasis and psoriasis (2 arms), sponsored by Novartis. Primary endpoint: Proportion achieving PASI 90 at week 32. Started Dec 2014; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2014-001974-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001974-32.